VYNE Therapeutics (VYNE) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
VYNE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
VYNE Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$1.96 |
| 52 Week Low | US$0.28 |
| Beta | 2 |
| 1 Month Change | 5.94% |
| 3 Month Change | 13.97% |
| 1 Year Change | -32.21% |
| 3 Year Change | -90.40% |
| 5 Year Change | -98.98% |
| Change since IPO | -99.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| VYNE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.1% | -0.3% |
| 1Y | -32.2% | 38.7% | 26.7% |
Return vs Industry: VYNE underperformed the US Pharmaceuticals industry which returned 38.7% over the past year.
Return vs Market: VYNE underperformed the US Market which returned 26.7% over the past year.
Price Volatility
| VYNE volatility | |
|---|---|
| VYNE Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VYNE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VYNE's weekly volatility has decreased from 16% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Dave Domzalski | vynetherapeutics.com |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions.
VYNE Therapeutics Inc. Fundamentals Summary
| VYNE fundamental statistics | |
|---|---|
| Market cap | US$22.55m |
| Earnings (TTM) | -US$21.72m |
| Revenue (TTM) | US$454.00k |
Is VYNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYNE income statement (TTM) | |
|---|---|
| Revenue | US$454.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$454.00k |
| Other Expenses | US$22.17m |
| Earnings | -US$21.72m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,783.70% |
| Debt/Equity Ratio | 0% |
How did VYNE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 00:56 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
VYNE Therapeutics Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Tsao | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Louise Chen | Guggenheim Securities, LLC |